TEMPORARY SUSPENSION FOR CLOSED-LOOP MEDICAMENT THERAPY

• US 20160030669A1
• Filed: 07/30/2015
• Published: 02/04/2016
• Est. Priority Date: 07/30/2014
• Status: Active Grant

• Current Assignee: Tandem Diabetes Care Incorporated
• Original Assignee: Tandem Diabetes Care Incorporated
• Inventors: Harris, Paul, Berger, David
• Granted Patent: US 9,669,160 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61M 2005/14208 with a programmable infusion control system, characterised by the infusion program
• CPC Class Codes: A61M 2205/502 User interfaces, e.g. screens or keyboards
• CPC Class Codes: A61M 2230/201 Glucose concentration
• CPC Class Codes: A61M 5/14244 adapted to be carried by the patient, e.g. portable on the body
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: G16H 20/17 delivered via infusion or injection
• CPC Class Codes: G16H 50/20 for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

A portable infusion pump can communicate with continuous glucose monitor (CGM) to receive continuous feedback relating to a user'"'"'s blood glucose level during insulin or other medicament therapy and can automatically deliver insulin to a user when the CGM data indicates a need for additional insulin. Because patient behavior can interfere with the accuracy and efficacy of such closed loop or semi-closed loop therapy, a system can employ various mechanisms for manual temporary suspension of closed-loop therapy when a patient is aware that current or future behavior may inhibit therapy.

Claims

1. An infusion pump system, comprising:

a delivery mechanism adapted to facilitate delivery of medicament to a patient;

memory adapted to store parameters relating to the delivery of medicament;

a communications device adapted to receive information from a continuous glucose monitor; and

a processor functionally linked to the delivery mechanism and the memory and to the communications device to obtain the information from the continuous glucose monitor, the processor configured to;

cause the delivery mechanism to deliver medicament to the patient according to therapy parameters determined based on the information from the continuous glucose monitor;

receive an indication that the patient is going to take or has taken a medication;

suspend delivery of medicament according to the determined therapy parameters for a suspension period in response to the indication;

cause the delivery mechanism to deliver medicament according to a default medicament delivery schedule stored in memory during the suspension period; and

resume causing the delivery mechanism to deliver medicament to the patient according to the determined therapy parameters following the suspension period.

2. The portable infusion pump of claim 1, wherein the processor is further configured to receive an indication of a type of medication the patient is going to take or has taken.

3. The portable infusion pump of claim 2, wherein the processor is further configured to determine whether the type of medication is one likely to cause the information from the continuous glucose monitor to become unreliable, and suspend delivery of medicament only if the type of medication is one likely to cause the information from the continuous glucose monitor to become unreliable.

4. The portable infusion pump of claim 1, wherein the processor is further configured to receive a duration for the suspension period entered through a user interface in communication with the processor.

5. The portable infusion pump of claim 2, wherein the processor is further configured to determine a duration for the suspension period based on the type of medication.

6. The portable infusion pump of claim 5, wherein the processor further determines the duration for the suspension period based on a dosage size of the medication.

7. The portable infusion pump of claim 1, wherein the processor is configured to resume causing the delivery mechanism to deliver medicament to the patient according to the determined therapy parameters automatically following the suspension period.

8. The portable infusion pump of claim 1, wherein the processor is further configured to provide a prompt on a user interface in communication with the processor that the suspension period has ended and to resume causing the delivery mechanism to deliver medicament to the patient according to the determined therapy parameters following the suspension period only after receiving a confirmation in response to the prompt.

9. The portable infusion pump of claim 1, wherein the processor is configured to determine the therapy parameters based on the information from the continuous glucose monitor.

10. A method of treating a patient with an infusion pump system, comprising:

causing a delivery mechanism of a portable infusion pump to deliver medicament to a patient according to therapy parameters determined based on information from a continuous glucose monitor;

receiving, at the portable infusion pump, an indication that the patient is going to take or has taken a medication;

suspending delivery of medicament by the portable infusion pump according to the determined therapy parameters for a suspension period in response to the indication;

causing the delivery mechanism to deliver medicament according to a default medicament delivery schedule stored in memory of the portable infusion pump during the suspension period; and

resuming causing the delivery mechanism to deliver medicament to the patient according to the determined therapy parameters following the suspension period.

11. The method of claim 10, further comprising receiving at the infusion pump an indication of a type of medication the patient is going to take or has taken.

12. The method of claim 11, further comprising determining whether the type of medication is one likely to cause the information from the continuous glucose monitor to become unreliable, and suspending delivery of medicament only if the type of medication is one likely to cause the information from the continuous glucose monitor to become unreliable.

13. The method of claim 10, further comprising receiving a duration for the suspension period through a user interface in communication with the processor.

14. The method of claim 11, further comprising determining a duration for the suspension period based on the type of medication.

15. The method of claim 14, wherein determining a duration for the suspension period includes determining the duration based on a dosage size of the medication.

16. The method of claim 10, wherein resuming causing the delivery mechanism to deliver medicament to the patient according to the determined therapy parameters includes automatically resuming following the suspension period.

17. The method of claim 10, further comprising providing a prompt on a user interface in communication with the processor that the suspension period has ended and resuming causing the delivery mechanism to deliver medicament to the patient according to the determined therapy parameters following the suspension period occurs only after receiving a confirmation in response to the prompt.

18. The method of claim 10, further comprising:

receiving, at the portable infusion pump, the information from the continuous glucose monitor; and

determining, at the portable infusion pump, the therapy parameters based on the information from the continuous glucose monitor.

19. An infusion pump system, comprising:

a delivery mechanism adapted to facilitate delivery of medicament to a patient;

memory adapted to store parameters relating to the delivery of medicament;

a communications device adapted to receive information from a continuous glucose monitor; and

a processor functionally linked to the delivery mechanism and the memory and to the communications device to obtain the information from the continuous glucose monitor, the processor configured to;

cause the delivery mechanism to deliver medicament to the patient according to therapy parameters determined based on the information from the continuous glucose monitor;

receive an indication that the patient is going to experience or has experienced a behavior or event that is likely to cause the information from the continuous glucose monitor to become unreliable;

suspend delivery of medicament according to the determined therapy parameters for a suspension period in response to the indication;

cause the delivery mechanism to deliver medicament according to a default medicament delivery schedule stored in memory during the suspension period; and

resume causing the delivery mechanism to deliver medicament to the patient according to the determined therapy parameters following the suspension period.

20. The portable infusion pump of claim 19, wherein the indication that the patient is going to experience or has experienced a behavior or event that is likely to cause the information from the continuous glucose monitor to become unreliable indicates that the behavior is ingesting a medication.

21. The portable infusion pump of claim 19, wherein the indication that the patient is going experience to or has experienced a behavior or event that is likely to cause the information from the continuous glucose monitor to become unreliable indicates that the behavior is excessive food consumption.

22. The portable infusion pump of claim 19, wherein the indication that the patient is going to experience or has experienced a behavior or event that is likely to cause the information from the continuous glucose monitor to become unreliable indicates that the behavior is binge drinking.

23. The portable infusion pump of claim 19, wherein the indication that the patient is going to experience or has experienced a behavior or event that is likely to cause the information from the continuous glucose monitor to become unreliable indicates that the behavior is excessive exercise.

24. The portable infusion pump of claim 19, wherein the indication that the patient is going to experience or has experienced a behavior or event that is likely to cause the information from the continuous glucose monitor to become unreliable indicates that the event is a patient illness.